246 related articles for article (PubMed ID: 21976245)
41. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
42. Chronic graft-versus-host disease: clinical manifestation and therapy.
Ratanatharathorn V; Ayash L; Lazarus HM; Fu J; Uberti JP
Bone Marrow Transplant; 2001 Jul; 28(2):121-9. PubMed ID: 11509929
[TBL] [Abstract][Full Text] [Related]
43. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Al-Homsi AS; Feng Y; Duffner U; Al Malki MM; Goodyke A; Cole K; Muilenburg M; Abdel-Mageed A
Exp Hematol; 2016 Sep; 44(9):771-777. PubMed ID: 27224851
[TBL] [Abstract][Full Text] [Related]
45. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
46. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
[TBL] [Abstract][Full Text] [Related]
47. Cardiac Graft Versus Host Disease: A Rare or Underrecognized Pathology?
Shrikhande B; Khosla J; Al-Kindi S; Asad ZUA; Al-Juhaishi T
Curr Probl Cardiol; 2023 Nov; 48(11):101807. PubMed ID: 37244510
[TBL] [Abstract][Full Text] [Related]
48. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
49. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Martin PJ; McDonald GB; Sanders JE; Anasetti C; Appelbaum FR; Deeg HJ; Nash RA; Petersdorf EW; Hansen JA; Storb R
Biol Blood Marrow Transplant; 2004 May; 10(5):320-7. PubMed ID: 15111931
[TBL] [Abstract][Full Text] [Related]
50. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
51. A Review of Ocular Graft-Versus-Host Disease.
Munir SZ; Aylward J
Optom Vis Sci; 2017 May; 94(5):545-555. PubMed ID: 28422804
[TBL] [Abstract][Full Text] [Related]
52. Acute graft-vs-host disease following liver transplantation.
Bitar C; Olivier K; Lee C; Vincent B; Martin J
Cutis; 2019 Jun; 103(6):E8-E11. PubMed ID: 31348462
[TBL] [Abstract][Full Text] [Related]
53. Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management.
Macedo FI; Faris J; Lum LG; Gabali A; Uberti JP; Ratanatharathorn V; White MT
J Burn Care Res; 2014; 35(6):e431-5. PubMed ID: 24476990
[TBL] [Abstract][Full Text] [Related]
54. Non-pharmacologic strategies in hematopoietic stem cell transplantation.
Schneiderman J
Curr Pharm Des; 2008; 14(20):1987-96. PubMed ID: 18691109
[TBL] [Abstract][Full Text] [Related]
55. Oral graft-versus-host disease.
Schubert MM; Correa ME
Dent Clin North Am; 2008 Jan; 52(1):79-109, viii-ix. PubMed ID: 18154866
[TBL] [Abstract][Full Text] [Related]
56. Oral graft-versus-host disease.
Kuten-Shorrer M; Woo SB; Treister NS
Dent Clin North Am; 2014 Apr; 58(2):351-68. PubMed ID: 24655527
[TBL] [Abstract][Full Text] [Related]
57. Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation.
Funke VA; Moreira MC; Vigorito AC
Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():44-50. PubMed ID: 27982319
[TBL] [Abstract][Full Text] [Related]
58. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.
Mielcarek M; Burroughs L; Leisenring W; Diaconescu R; Martin PJ; Sandmaier BM; Maloney DG; Maris MB; Chauncey TR; Shizuru JA; Blume KG; Hegenbart U; Niederwieser D; Forman S; Bruno B; Woolfrey A; Storb R
Br J Haematol; 2005 May; 129(3):381-91. PubMed ID: 15842663
[TBL] [Abstract][Full Text] [Related]
59. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
[TBL] [Abstract][Full Text] [Related]
60. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
